<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Tango Therapeutics, Inc. — News on 6ix</title>
<link>https://6ix.com/company/tango-therapeutics-inc</link>
<description>Latest news and press releases for Tango Therapeutics, Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 15 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/tango-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835cb3878dffbe2df11d112.webp</url>
<title>Tango Therapeutics, Inc.</title>
<link>https://6ix.com/company/tango-therapeutics-inc</link>
</image>
<item>
<title>Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of Vopimetostat</title>
<link>https://6ix.com/company/tango-therapeutics-inc/news/tango-therapeutics-announces-leadership-appointments-to-accelerate-late-stage-development-of-vopimetostat</link>
<guid isPermaLink="true">https://6ix.com/company/tango-therapeutics-inc/news/tango-therapeutics-announces-leadership-appointments-to-accelerate-late-stage-development-of-vopimetostat</guid>
<pubDate>Wed, 15 Apr 2026 04:00:00 GMT</pubDate>
<description>- Matthew Gall appointed Chief Financial Officer -- Additional key appointments add expertise in clinical operations, corporate strategy and project</description>
</item>
<item>
<title>Erasca and Tango Therapeutics Enter into Clinical Collaboration to Evaluate Combination of ERAS-0015 and Vopimetostat</title>
<link>https://6ix.com/company/tango-therapeutics-inc/news/erasca-and-tango-therapeutics-enter-into-clinical-collaboration-to-evaluate-combination-of-eras-0015-and-vopimetostat-12</link>
<guid isPermaLink="true">https://6ix.com/company/tango-therapeutics-inc/news/erasca-and-tango-therapeutics-enter-into-clinical-collaboration-to-evaluate-combination-of-eras-0015-and-vopimetostat-12</guid>
<pubDate>Thu, 05 Mar 2026 12:01:00 GMT</pubDate>
<description>ERAS-0015, a pan-RAS molecular glue, will be evaluated in combination with PRMT5 inhibitor vopimetostat Tango will sponsor the clinical trial and Erasca will supply ERAS-0015 at no cost SAN DIEGO, March 05, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced a clinical trial collaboration and supply agreement</description>
</item>
<item>
<title>Tango Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights</title>
<link>https://6ix.com/company/tango-therapeutics-inc/news/tango-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-highlights-6</link>
<guid isPermaLink="true">https://6ix.com/company/tango-therapeutics-inc/news/tango-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-highlights-6</guid>
<pubDate>Thu, 05 Mar 2026 05:00:00 GMT</pubDate>
<description>Initial Phase 1/2 trial data of vopimetostat in combination with Revolution Medicines’ RAS(ON) inhibitors in MTAP-deleted pancreatic cancer in 2026 with</description>
</item>
<item>
<title>Tango Therapeutics to Report Fourth Quarter 2025 Financial Results and Participate in Three Upcoming Investor Conferences</title>
<link>https://6ix.com/company/tango-therapeutics-inc/news/tango-therapeutics-to-report-fourth-quarter-2025-financial-results-and-participate-in-three-upcoming-investor-conferences</link>
<guid isPermaLink="true">https://6ix.com/company/tango-therapeutics-inc/news/tango-therapeutics-to-report-fourth-quarter-2025-financial-results-and-participate-in-three-upcoming-investor-conferences</guid>
<pubDate>Wed, 18 Feb 2026 05:00:00 GMT</pubDate>
<description>BOSTON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that it will report fourth quarter 2025 financial results</description>
</item>
<item>
<title>Tango Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026</title>
<link>https://6ix.com/company/tango-therapeutics-inc/news/tango-therapeutics-participate-guggenheim-emerging-outlook-biotech-summit-2026-2026</link>
<guid isPermaLink="true">https://6ix.com/company/tango-therapeutics-inc/news/tango-therapeutics-participate-guggenheim-emerging-outlook-biotech-summit-2026-2026</guid>
<pubDate>Tue, 03 Feb 2026 05:00:00 GMT</pubDate>
<description>BOSTON, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Malte Peters, M.D., President and Chief Executive</description>
</item>
<item>
<title>Tango Therapeutics Announces CEO Transition: Barbara Weber to Retire, Malte Peters Appointed Successor</title>
<link>https://6ix.com/company/tango-therapeutics-inc/news/tango-therapeutics-announces-ceo-transition-140500024</link>
<guid isPermaLink="true">https://6ix.com/company/tango-therapeutics-inc/news/tango-therapeutics-announces-ceo-transition-140500024</guid>
<pubDate>Thu, 08 Jan 2026 14:05:00 GMT</pubDate>
<description>Founding CEO Barbara Weber, M.D. to become executive chair of the board of directorsMalte Peters, M.D., current board member, appointed President and Chief Executive Officer, effective immediately – BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines today announced the retirement of its Chief Executive Officer, Dr. Barbara Weber, effecti</description>
</item>
<item>
<title>Tango Therapeutics Appoints Sung Lee to Board of Directors</title>
<link>https://6ix.com/company/tango-therapeutics-inc/news/tango-therapeutics-appoints-sung-lee-board-directors-2026-01-05</link>
<guid isPermaLink="true">https://6ix.com/company/tango-therapeutics-inc/news/tango-therapeutics-appoints-sung-lee-board-directors-2026-01-05</guid>
<pubDate>Mon, 05 Jan 2026 05:00:00 GMT</pubDate>
<description>BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and</description>
</item>
<item>
<title>Tango Therapeutics to Participate in 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/tango-therapeutics-inc/news/tango-therapeutics-participate-44th-annual-jp-morgan-healthcare-conference-2025-12-17</link>
<guid isPermaLink="true">https://6ix.com/company/tango-therapeutics-inc/news/tango-therapeutics-participate-44th-annual-jp-morgan-healthcare-conference-2025-12-17</guid>
<pubDate>Wed, 17 Dec 2025 05:00:00 GMT</pubDate>
<description>BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Barbara Weber, M.D., President and Chief Executive</description>
</item>
<item>
<title>Tango Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference</title>
<link>https://6ix.com/company/tango-therapeutics-inc/news/tango-therapeutics-participate-piper-sandler-37th-annual-healthcare-conference-2025</link>
<guid isPermaLink="true">https://6ix.com/company/tango-therapeutics-inc/news/tango-therapeutics-participate-piper-sandler-37th-annual-healthcare-conference-2025</guid>
<pubDate>Wed, 26 Nov 2025 05:00:00 GMT</pubDate>
<description>BOSTON, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Adam Crystal, M.D., Ph.D., President of Research &</description>
</item>
<item>
<title>Tango Therapeutics to Participate in the 2025 Jefferies Global Healthcare Conference</title>
<link>https://6ix.com/company/tango-therapeutics-inc/news/tango-therapeutics-participate-2025-jefferies-global-healthcare-conference-2025-11-12</link>
<guid isPermaLink="true">https://6ix.com/company/tango-therapeutics-inc/news/tango-therapeutics-participate-2025-jefferies-global-healthcare-conference-2025-11-12</guid>
<pubDate>Wed, 12 Nov 2025 05:00:00 GMT</pubDate>
<description>BOSTON, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Barbara Weber, M.D., President and Chief Executive</description>
</item>
<item>
<title>Tango Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights</title>
<link>https://6ix.com/company/tango-therapeutics-inc/news/tango-therapeutics-reports-third-quarter-2025-financial-results-and-provides-business</link>
<guid isPermaLink="true">https://6ix.com/company/tango-therapeutics-inc/news/tango-therapeutics-reports-third-quarter-2025-financial-results-and-provides-business</guid>
<pubDate>Tue, 04 Nov 2025 05:00:00 GMT</pubDate>
<description>– Data update from vopimetostat (TNG462) showed 2L MTAP-del pancreatic cancer median progression free survival (mPFS) 7.2 months– – Combination studies with</description>
</item>
<item>
<title>Tango Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025</title>
<link>https://6ix.com/company/tango-therapeutics-inc/news/tango-therapeutics-report-third-quarter-2025-financial-results-tuesday-november-4</link>
<guid isPermaLink="true">https://6ix.com/company/tango-therapeutics-inc/news/tango-therapeutics-report-third-quarter-2025-financial-results-tuesday-november-4</guid>
<pubDate>Wed, 29 Oct 2025 04:00:00 GMT</pubDate>
<description>BOSTON, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that it will report third quarter 2025 financial results on</description>
</item>
<item>
<title>Tango Therapeutics Announces $225 Million Financing</title>
<link>https://6ix.com/company/tango-therapeutics-inc/news/tango-therapeutics-announces-225-million-financing-2025-10-23</link>
<guid isPermaLink="true">https://6ix.com/company/tango-therapeutics-inc/news/tango-therapeutics-announces-225-million-financing-2025-10-23</guid>
<pubDate>Thu, 23 Oct 2025 04:00:00 GMT</pubDate>
<description>Financing participants include Farallon Capital Management, TCGX, Balyasny Asset Management, Woodline Partners LP, Nextech, Invus, Adage Capital Management</description>
</item>
<item>
<title>Tango Therapeutics Reports Positive Data from Ongoing Phase 1/2 Study with Vopimetostat (TNG462) in Patients with MTAP-deleted Cancers</title>
<link>https://6ix.com/company/tango-therapeutics-inc/news/tango-therapeutics-reports-positive-data-ongoing-phase-1-2-study-vopimetostat-tng462</link>
<guid isPermaLink="true">https://6ix.com/company/tango-therapeutics-inc/news/tango-therapeutics-reports-positive-data-ongoing-phase-1-2-study-vopimetostat-tng462</guid>
<pubDate>Thu, 23 Oct 2025 04:00:00 GMT</pubDate>
<description>– 2L MTAP-del pancreatic cancer median progression free survival (mPFS) 7.2 months with an objective response rate (ORR) of 25% – – Combination studies with</description>
</item>
<item>
<title>Tango Therapeutics to Present First Clinical Data from TNG260 at Society for Immunotherapy of Cancer (SITC) Annual Meeting 2025</title>
<link>https://6ix.com/company/tango-therapeutics-inc/news/tango-therapeutics-present-first-clinical-data-tng260-society-immunotherapy-cancer</link>
<guid isPermaLink="true">https://6ix.com/company/tango-therapeutics-inc/news/tango-therapeutics-present-first-clinical-data-tng260-society-immunotherapy-cancer</guid>
<pubDate>Mon, 06 Oct 2025 04:00:00 GMT</pubDate>
<description>Company to present three posters at SITC Annual Meeting 2025 BOSTON, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a</description>
</item>
<item>
<title>Tango Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference</title>
<link>https://6ix.com/company/tango-therapeutics-inc/news/tango-therapeutics-participate-2025-cantor-global-healthcare-conference-2025-08-26</link>
<guid isPermaLink="true">https://6ix.com/company/tango-therapeutics-inc/news/tango-therapeutics-participate-2025-cantor-global-healthcare-conference-2025-08-26</guid>
<pubDate>Tue, 26 Aug 2025 04:00:00 GMT</pubDate>
<description>BOSTON, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Barbara Weber, M.D., President and Chief Executive</description>
</item>
<item>
<title>Tango Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights</title>
<link>https://6ix.com/company/tango-therapeutics-inc/news/tango-therapeutics-reports-second-quarter-110000917</link>
<guid isPermaLink="true">https://6ix.com/company/tango-therapeutics-inc/news/tango-therapeutics-reports-second-quarter-110000917</guid>
<pubDate>Tue, 05 Aug 2025 11:00:00 GMT</pubDate>
<description>– First patient dosed in combination trial of TNG462 and Revolution Medicines RAS(ON) inhibitors – – First patient dosed in Phase 1/2 trial with TNG456, a brain-penetrant MTA-cooperative PRMT5 inhibitor in development for glioblastoma – BOSTON, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today reported financial results for the second qu</description>
</item>
<item>
<title>Tango Therapeutics to Report Second Quarter 2025 Financial Results on Tuesday, August 5, 2025</title>
<link>https://6ix.com/company/tango-therapeutics-inc/news/tango-therapeutics-report-second-quarter-2025-financial-results-tuesday-august-5-2025</link>
<guid isPermaLink="true">https://6ix.com/company/tango-therapeutics-inc/news/tango-therapeutics-report-second-quarter-2025-financial-results-tuesday-august-5-2025</guid>
<pubDate>Tue, 22 Jul 2025 04:00:00 GMT</pubDate>
<description>BOSTON, July 22, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that it will report second quarter 2025 financial results</description>
</item>
<item>
<title>Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG462 plus Revolution Medicines’ Daraxonrasib or Zoldonrasib in Patients with RAS-Mutant MTAP-deleted Pancreatic or Lung Cancer</title>
<link>https://6ix.com/company/tango-therapeutics-inc/news/tango-therapeutics-announces-first-patient-dosed-phase-1-2-trial-tng462-plus</link>
<guid isPermaLink="true">https://6ix.com/company/tango-therapeutics-inc/news/tango-therapeutics-announces-first-patient-dosed-phase-1-2-trial-tng462-plus</guid>
<pubDate>Fri, 27 Jun 2025 04:00:00 GMT</pubDate>
<description>BOSTON, June 27, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering the next</description>
</item>
<item>
<title>Tango Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference</title>
<link>https://6ix.com/company/tango-therapeutics-inc/news/tango-therapeutics-participate-46th-annual-goldman-sachs-global-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/tango-therapeutics-inc/news/tango-therapeutics-participate-46th-annual-goldman-sachs-global-healthcare-conference</guid>
<pubDate>Tue, 27 May 2025 04:00:00 GMT</pubDate>
<description>BOSTON, May 27, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Barbara Weber, M.D., President and Chief Executive</description>
</item>
</channel>
</rss>